QED

    OverviewSuggest Edit

    QED is a regional electrical distributor. The Company serves residential and commercial contractors, industrial facilities, and OEM businesses.

    TypePrivate
    Founded1987
    HQDenver, CO, USMap
    Websiteqedelectric.com

    Recent NewsAll News

    Latest Updates

    Employees (est.) (Apr 2019)280
    Cybersecurity ratingAMore

    QED Office Locations

    QED has offices in Denver, Broomfield, Centennial, Colorado Springs and in 6 other locations
    Denver, CO, US (HQ)
    1661 W 3rd Ave
    Broomfield, CO, US
    1785 W 160th Ave
    Centennial, CO, US
    7000 S Jordan Rd
    Colorado Springs, CO, US
    1340 Ford St
    Grand Junction, CO, US
    1440 Winters Ave
    Las Vegas, NV, US
    5875 S Decatur Blvd
    Show all (10)

    QED Financials and Metrics

    Summary Metrics

    Founding Date

    		1987

    QED Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    92/100

    Learn more about our premium products
    SecurityScorecard logo

    QED Online and Social Media Presence

    QED's Trends

    Embed Graph

    QED News and Updates

    July 28, 2020

    Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma

    PHOENIX and SAN FRANCISCO, July 28, 2020 (GLOBE NEWSWIRE) -- Ivy Brain Tumor Center at Barrow Neurological Institute announced today that the first patient has been dosed in an investigator-initiated Phase 0/2 clinical trial of infigratinib in recurrent high-grade glioma driven by FGFR genetic alt…
    March 12, 2020

    BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations

    PROOF 302 Trial Enrolling Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations
    January 06, 2020

    BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma

    The PROOF trial, a Phase 3 trial of infigratinib in first-line cholangiocarcinoma, is currently enrolling The PROOF trial, a Phase 3 trial of infigratinib in first-line cholangiocarcinoma, is currently enrolling
    October 04, 2019

    Finalists named in the Science Centers QED Proof-of-Concept Program for Academic Researchers

    PHILADELPHIA--(October 4, 2019)-- The University City Science Center has named 10 finalists in its 2019 QED proof-of-concept program, which partners with regional academic and research institutions to prepare their most promising life science technologies for commercialization. read more
    September 03, 2019

    Broadband Forum leaps forward in the pursuit of better broadband quality of experience with its QED and ALT initiatives

    MILAN, Italy, Sept. 3, 2019 /PRNewswire/ -- Significant progress in efforts to enhance the quality of the broadband user experience was reached today at the Broadband Forum Q3 meeting in Milan. In a first-of-its-kind Practical Implementation Demonstration as part of Broadband Forum's...

     QED Frequently Asked Questions

    • When was QED founded?

      QED was founded in 1987.

    • How many employees does QED have?

      QED has 280 employees.

    • Who are QED competitors?

      Competitors of QED include Ixina, Sevam and OPPLE.

    • Where is QED headquarters?

      QED headquarters is located at 1661 W 3rd Ave, Denver.

    • Where are QED offices?

      QED has offices in Denver, Broomfield, Centennial, Colorado Springs and in 6 other locations.

    • How many offices does QED have?

      QED has 10 offices.